Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00038441

Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas

Phase I Trial of Intratumoral Injection of DTI-015 for Recurrent Malignant Gliomas

Sponsor: Direct Therapeutics

Interventions DTI-015

Updated 7 times since 2017 Last updated: Oct 30, 2018 Started: Sep 30, 1995 Primary completion: Feb 28, 2003 Completion: Aug 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00038441, this PHASE1/PHASE2 trial focuses on Brain Neoplasms and Glioma and remains completed. Sponsored by Direct Therapeutics, it has been updated 7 times since 1995, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Nov 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Nov 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Sep 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Direct Therapeutics
M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States